

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A packaged tablet, which tablet has a matrix ~~consisting of~~ comprising at least 55% of a cellulose ether, wherein the tablet has a water activity of at most 0.6 and is packaged such as to delay moisture uptake by the tablet.

2. (Previously Presented) The packaged tablet according to claim 1, wherein the tablet has a water activity of less than 0.55.

3. (Currently Amended) A packaged tablet, which tablet has a matrix ~~consisting of~~ comprising at least 55% of a cellulose ether, wherein the tablet has a water content of less than 9% w/w and is packaged such as to delay moisture uptake by the tablet.

4. (Currently Amended) The packaged tablet according to claim 1, wherein the matrix ~~consists of~~ comprises more than 65% of a cellulose ether.

5. (Previously Presented) The packaged tablet according to claim 4, wherein the cellulose ether is hydroxypropyl methylcellulose.

6. (Currently Amended) The packaged tablet according to claim 1, wherein the tablet comprises gepirone HCl in an amount in the range of from ~~20-85 mg~~ 20-85 mg.

7. (Currently Amended) The packaged tablet according to claim 3, wherein the matrix ~~consists of~~ comprises more than 65% of a cellulose ether.

8. (Currently Amended) The packaged tablet according to claim 3, wherein the tablet comprises gepirone HCl in an amount in the range of from ~~20-85 ma~~ 20-85 mg.

9. (Currently Amended) The packaged tablet according to claim 1, wherein the tablet comprises gepirone HCl in an amount in the range of from ~~20-85 ma~~ 20-85 mg and the matrix ~~consists of~~ comprises more than 65% of a cellulose ether.

10. (Previously Presented) The packaged tablet according to claim 9, wherein the cellulose ether is hydroxypropyl methylcellulose.

11. (New) The packaged tablet according to claim 1, wherein the matrix comprises 70 to 85% of a cellulose ether.

12. (New) The packaged tablet according to claim 1, wherein the tablet comprises gepirone HCl in an amount in the range of from 60-85 mg.

13. (New) The packaged tablet according to claim 1, wherein the matrix further comprises microcrystalline cellulose.

14. (New) The packaged tablet according to claim 1, wherein the matrix further comprises euroxide, yellow ferric oxide, and/or red ferric oxide.

15. (New) The packaged tablet according to claim 1, wherein the matrix further comprises colloidal anhydrous silicon dioxide.

16. (New) The packaged tablet according to claim 1, wherein the matrix further comprises magnesium stearate.

17. (New) The packaged tablet according to claim 3, wherein the matrix comprises 70 to 85% of a cellulose ether.

18. (New) The packaged tablet according to claim 3, wherein the tablet comprises gepirone HCl in an amount in the range of from 60-85 mg.

19. (New) The packaged tablet according to claim 3, wherein the matrix further comprises microcrystalline cellulose.

20. (New) The packaged tablet according to claim 3, wherein the matrix further comprises euroxide, yellow ferric oxide, and/or red ferric oxide.

21. (New) The packaged tablet according to claim 3, wherein the matrix further comprises colloidal anhydrous silicon dioxide.

22. (New) The packaged tablet according to claim 3, wherein the matrix further comprises magnesium stearate.

SUPPORT FOR THE AMENDMENTS

Claims 1, 3, 4, and 6-9 have been amended.

Claims 11-22 have been added.

The amendment of Claims 1, 3, 4, and 6-9 and new Claims 11-22 is supported by the originally filed claims and by the specification at pages 2, line 29 to page 4, line 30 and Table 1 on page 5.

No new matter has been entered by the present amendment.